昭衍新药发盈喜预期上半年归母净利约5032.43万元到7548.65万元实现扭亏为盈

智通财经2025-07-14

智通财经APP讯，昭衍新药(06127)公布，预计2025年1-6月份实现营业收入约人民币6.35亿-7.02亿元，同比下降约17.3%到25.2%。预计2025年1-6月份实现归属于上市公司股东的净利润约人民币5032.43万元到7548.65万元，扣除非经常性损益的净利润约人民币1883.19万元到2824.79万元，将实现扭亏为盈。公告称，业绩变动主要由于本报告期内受同业竞争影响，公司营业...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2551032186?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-14 19:30","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2551032186","market":"sh","top_or_hot":-1,"title":"昭衍新药发盈喜 预期上半年归母净利约5032.43万元到7548.65万元 实现扭亏为盈","media":"智通财经","content":"<div>\n<p>智通财经APP讯，昭衍新药(06127)公布，预计2025年1-6月份实现营业收入约人民币6.35亿-7.02亿元，同比下降约17.3%到25.2%。预计2025年1-6月份实现归属于上市公司股东的净利润约人民币5032.43万元到7548.65万元，扣除非经常性损益的净利润约人民币1883.19万元到2824.79万元，将实现扭亏为盈。公告称，业绩变动主要由于本报告期内受同业竞争影响，公司营业...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071419331195420baa&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>昭衍新药发盈喜 预期上半年归母净利约5032.43万元到7548.65万元 实现扭亏为盈</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n昭衍新药发盈喜 预期上半年归母净利约5032.43万元到7548.65万元 实现扭亏为盈\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-14 19:30 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071419331195420baa&s=b><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，昭衍新药(06127)公布，预计2025年1-6月份实现营业收入约人民币6.35亿-7.02亿元，同比下降约17.3%到25.2%。预计2025年1-6月份实现归属于上市公司股东的净利润约人民币5032.43万元到7548.65万元，扣除非经常性损益的净利润约人民币1883.19万元到2824.79万元，将实现扭亏为盈。公告称，业绩变动主要由于本报告期内受同业竞争影响，公司营业...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071419331195420baa&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0216","symbol_name":"研究试验","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071419331195420baa&s=b","article_id":"2551032186","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071419331195420baa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2551032186","pubTimestamp":1752492629,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"智通财经APP讯，昭衍新药(06127)公布，预计2025年1-6月份实现营业收入约人民币6.35亿-7.02亿元，同比下降约17.3%到25.2%。预计2025年1-6月份实现归属于上市公司股东的净利润约人民币5032.43万元到7548.65万元，扣除非经常性损益的净利润约人民币1883.19万元到2824.79万元，将实现扭亏为盈。公告称，业绩变动主要由于本报告期内受同业竞争影响，公司营业收入有所下降，销售订单的利润空间被压缩，毛利率同比降低，实验室服务业务净利润同比下降，发生亏损。本报告期内公司持有的生物资产市价无重大波动，生物资产自然生长带来的公允价值变动收益对业绩产生积极影响。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603127":"昭衍新药","BK0216":"研究试验"},"translate_title":"Zhaoyan New Drug issued a profit report, expecting the net profit attributable to the parent company in the first half of the year to be approximately 50.3243 million yuan to 75.4865 million yuan, turning losses into profits","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603127":1},"content_text":"智通财经APP讯，昭衍新药(06127)公布，预计2025年1-6月份实现营业收入约人民币6.35亿-7.02亿元，同比下降约17.3%到25.2%。预计2025年1-6月份实现归属于上市公司股东的净利润约人民币5032.43万元到7548.65万元，扣除非经常性损益的净利润约人民币1883.19万元到2824.79万元，将实现扭亏为盈。公告称，业绩变动主要由于本报告期内受同业竞争影响，公司营业收入有所下降，销售订单的利润空间被压缩，毛利率同比降低，实验室服务业务净利润同比下降，发生亏损。本报告期内公司持有的生物资产市价无重大波动，生物资产自然生长带来的公允价值变动收益对业绩产生积极影响。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2551032186","isCrawlerRequest":true}

昭衍新药发盈喜 预期上半年归母净利约5032.43万元到7548.65万元 实现扭亏为盈

精彩评论

昭衍新药发盈喜预期上半年归母净利约5032.43万元到7548.65万元实现扭亏为盈